HomeAnalysisCSG’s €17bn Order Backlog Fails to Shift Momentum as Analysts Hold Their...

CSG’s €17bn Order Backlog Fails to Shift Momentum as Analysts Hold Their Ground

The Czechoslovak Group (CSG) finds itself in a peculiar spot: first-quarter numbers that would normally spark a rally have instead been met with deepening skepticism. The defence and aviation conglomerate reported a 13.8% jump in revenue to €1.54bn for the opening three months of the year, while net profit surged 83% to €299mn. Yet the stock has haemorrhaged value since January, losing more than half its peak of €33.81. It recently changed hands at €15.77, perilously close to a 52-week low.

The pressure stems from an uneven performance across individual business lines. Berenberg, updating its model after the Q1 release, trimmed its price target but kept a buy recommendation. The bank’s caution reflects weaker-than-expected results in certain segments, even as the Defence Systems division — CSG’s largest unit — delivered a 26% revenue increase to €1.25bn. The unit’s order backlog swelled 15% since year-end to approximately €17bn, a figure that would typically reassure investors.

Ten analysts covering the stock still rate it a strong buy, with a consensus price target of €32.05 — implying a potential upside of roughly 100% from current levels. Such a wide gap between street expectations and market reality raises uncomfortable questions about what the sell side is seeing that traders are not.

Technically, the chart looks strained. The shares trade around 22% below their 50-day moving average, and the annualised 30-day volatility has spiked past 80% — extreme for an industrial name. The weekly slide of 9.7% underscores how little conviction exists near the lows. CSG is now only 2.2% above its most recent trough.

Should investors sell immediately? Or is it worth buying CSG?

Management has not been idle. Through a mix of voting rights and total-return swaps, the group raised its economic interest in chemicals company AlzChem to roughly 20.1%, signaling a continued appetite for strategic expansion despite the near-term operational hiccups.

External catalysts may help shift sentiment. In Plovdiv, Bulgaria, the HEMUS 2026 defence exhibition kicked off this week, drawing 216 exhibitors from 28 countries, including 18 Czech firms. The show, opened by President Iliana Iotova, covers more than 5,000 square metres and focuses on robotics, artificial intelligence and drone systems — areas increasingly pivotal for European defence procurement. High-level forums and live-fire demonstrations are scheduled, with over 16 international delegations attending. For CSG, the event offers a chance to reinforce its credibility as a regional powerhouse at a time when the market demands more than a full order book.

The next real test will come with second-quarter results. Whether the weaker segments can close the gap with the analyst consensus will determine if the stock has found a bottom — or if the disconnect between operational strength and share price performance will widen further.

Ad

CSG Stock: Buy or Sell?! New CSG Analysis from June 3 delivers the answer:

The latest CSG figures speak for themselves: Urgent action needed for CSG investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 3.

CSG: Buy or sell? Read more here...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Must Read

spot_img